Eli Lilly Strikes Up to USD 3.35 Bn Deal With InnoCare for New Drug Discovery
Shanghai: Chinese drugmaker InnoCare Pharma said on Thursday it had entered into a research collaboration and licensing agreement with Eli Lilly worth up to about USD 3.35 billion.
InnoCare would receive up to $100 million in upfront and near-term payments and about $3.25 billion in development and commercial milestone payments, plus tiered, single-digit royalties on future annual net product sales.
The Beijing-based firm said it would develop new medicines leveraging its drug discovery platform to discover and advance compounds against up to five targets, as part of the deal.
InnoCare specialises in drugs for the treatment of cancer and autoimmune diseases.
A spokesperson for Eli Lilly did not immediately respond to a request for comment on what specific disease areas would be targeted in the collaboration.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.